Ernest V. Linek discusses Merck’s unsuccessful move to invalidate a Bristol-Myers Squibb patent covering metastatic skin cancer treatment in Life Sciences Intellectual Property Review.
In his article, Mr. Linek points out that the court’s action may signal to the pharmaceutical industry that some methods of treatment claims, such as those in the BMS patent, can be the subject of Section 101 ineligiblity analysis.
Please click here to read the article. Registration is required.
Posted: April 7, 2016